Mankind Pharma shares key business developments from Q2 & H1 of FY27
Reported by Economic Times Industry, not nibnow. We are not the publisher of this story, only the source is.
Mankind Pharma’s strong outperformance in chronic and acute therapy segments signals robust growth that could impact investors and the broader pharma market.
The company outperformed the market by 1.1 times in both chronic and acute therapies. Cardiac and anti-diabetes brands registered growth of 18.7% and 15.8%, respectively. In acute therapies, gastroenterology grew at 1.3 times the market rate, while vitamins, minerals and nutrients (VMN) expanded at 1.4 times that rate.
Mankind Pharma is an Indian pharmaceutical firm that develops and sells medicines across therapeutic areas; market‑outperformance metrics compare a company's sales growth to the overall industry rate, indicating competitive strength.
- •Future quarterly earnings releases to see if growth trends continue
- •Potential updates on the performance of its cardiac, anti‑diabetes and gastroenterology brands
- •Any guidance the company provides for the remainder of FY27